A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Merck Sharp & Dohme LLC · NCT07463183
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 100
- US sites recruiting
- 11
- Study start
- March 24, 2026
- Record last updated
- October 23, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Being studied: MK-8690; Placebo
Conditions: Colitis Ulcerative; Ulcerative Colitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
The main inclusion criteria include but are not limited to the following:
- Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization
- Has moderately to severely active UC
- Has a weight ≥40 kg
- Satisfies at least 1 of the criteria: Has had an inadequate response or loss of response to 1 or more protocol-specified treatments; protocol specified corticosteroid dependence; has been intolerant to 1 or more protocol-specified UC treatments
- Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable
The main exclusion criteria include but are not limited to the following:
- Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment
- Has a current diagnosis of fulminant colitis and/or toxic megacolon
- Has UC limited to the rectum
- Has a current or impending need for colostomy or ileostomy
- Has had a total proctocolectomy or partial colectomy
- Has UC exacerbation requiring hospitalization within 2 weeks before Screening
- Has any active infection as specified in the protocol
- Is known to be infected with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- Has evidence of active tuberculosis (TB) or meets TB exclusionary parameters
- Has a history of cancer (except fully treated nonmelanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \<5 years before Randomization or has a history of colorectal cancer at any time
- Has prior or current evidence of definite colonic dysplasia except for low-grade dysplasia that has been completely removed
- Has had major surgery within 3 months before Screening or has a major surgery (ie, surgical procedure requiring general anesthesia) planned during the study
- Has received protocol-specified prohibited medications
Recruiting US locations
Clinnova Research ( Site 1042)
Anaheim, CA 92805
Site contact: Study Coordinator · 949-889-0249
Southern California Research Center ( Site 1044)
Coronado, CA 92118
Site contact: Study Coordinator · 619-522-0330
Peak Gastroenterology Associates ( Site 1052)
Colorado Springs, CO 80907
Site contact: Study Coordinator · 719-636-1201
South Denver Gastroenterology, PC ( Site 1068)
Englewood, CO 80113
Site contact: Study Coordinator · 303-406-4288
Nature Coast Clinical Research ( Site 1045)
Inverness, FL 34452
Site contact: Study Coordinator · 352-341-2100
Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072)
Miami, FL 33134
Site contact: Study Coordinator · 786-476-8790
AdventHealth Orlando ( Site 1074)
Orlando, FL 32803
Site contact: Study Coordinator · 407-303-9921
Gastroenterology Associates of Central Georgia ( Site 1060)
Macon, GA 31201
Site contact: Study Coordinator · 478-464-2600
University of Kansas Medical Center ( Site 1077)
Kansas City, KS 66160
Site contact: Study Coordinator · 913-588-6019
Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073)
New Orleans, LA 70112
Site contact: Study Coordinator · 504-988-5110
BVL Research - Kansas ( Site 1054)
Liberty, MO 64068
Site contact: Study Coordinator · 816-222-4241
Study contacts (from the official record)
- Toll Free Number · 1-888-577-8839 · Trialsites@msd.com